Výsledky vyhledávání - "Sarmishtha De"

Data from Quinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT, NF-κB, and Cell-Cycle Progression in Non–Small Cell Lung Cancer

Autor: George R. Stark, Neelesh Sharma, Goutham Narla, Sarmishtha De, Afshin Dowlati, John Pink, Katerina Gurova, Josephine Kam Tai Dermawan

Erlotinib is a tyrosine kinase inhibitor approved for the treatment of patients with advanced non–small cell lung cancer (NSCLC). In these patients, erlotinib prolongs survival but its benefit remains modest because many tumors express wild-type (w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ddaf68264ee91f07e1b7e103962e6cec
https://doi.org/10.1158/1535-7163.c.6536799.v1

Zobrazit plný text záznamu

Fig. S1 from The FACT inhibitor CBL0137 Synergizes with Cisplatin in Small-Cell Lung Cancer by Increasing NOTCH1 Expression and Targeting Tumor-Initiating Cells

Autor: George R. Stark, Afshin Dowlati, Gary Wildey, Claire J. Coleman, Daniel J. Lindner, Sarmishtha De

Supplementary Fig S1. CBL0137 in combination with cisplatin attenuates SCLC tumor growth. H82 SCLC cells, mixed with Matrigel (1:1), were inoculated subcutaneously into the flanks of NSG mice (n=8). Once the tumors reached â^¼50 mm3, the mice were

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cd5bee1b3ca0892a474adad7850c391
https://doi.org/10.1158/0008-5472.22417206.v1

Zobrazit plný text záznamu

Fig. S2 from The FACT inhibitor CBL0137 Synergizes with Cisplatin in Small-Cell Lung Cancer by Increasing NOTCH1 Expression and Targeting Tumor-Initiating Cells

Autor: George R. Stark, Afshin Dowlati, Gary Wildey, Claire J. Coleman, Daniel J. Lindner, Sarmishtha De

Supplementary Fig S2. SCLC TICs are enriched for stem cell markers. A, B, C, Expression levels of SOX2, NANOG and OCT4 mRNAs in CD133high and CD133low H82 (A) and H526 (B) cells or CD44high and CD44low H446 (C) cells. D, Levels of SOX2 and OCT4, dete

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25641035cf902833a9872d743a1bda6a
https://doi.org/10.1158/0008-5472.22417203

Zobrazit plný text záznamu

Fig. S3 from The FACT inhibitor CBL0137 Synergizes with Cisplatin in Small-Cell Lung Cancer by Increasing NOTCH1 Expression and Targeting Tumor-Initiating Cells

Autor: George R. Stark, Afshin Dowlati, Gary Wildey, Claire J. Coleman, Daniel J. Lindner, Sarmishtha De

Supplementary Fig S3. CBL0137 inhibits FACT function in SCLC TICs. A, SSRP1 levels were determined by Western analysis in CD133high or CD133low cells from H82 or H526. Î²-actin was used as a loading control. B, H82 CD133high cells were treated with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a65c53d38298779b9a2c26014d62e0f
https://doi.org/10.1158/0008-5472.22417200.v1

Zobrazit plný text záznamu

Data from The FACT inhibitor CBL0137 Synergizes with Cisplatin in Small-Cell Lung Cancer by Increasing NOTCH1 Expression and Targeting Tumor-Initiating Cells

Autor: George R. Stark, Afshin Dowlati, Gary Wildey, Claire J. Coleman, Daniel J. Lindner, Sarmishtha De

Traditional treatments of small-cell lung cancer (SCLC) with cisplatin, a standard-of-care therapy, spare the tumor-initiating cells (TIC) that mediate drug resistance. Here we report a novel therapeutic strategy that preferentially targets TICs in S

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0be846d6e9f0619530b7d5a499b28974
https://doi.org/10.1158/0008-5472.c.6509775

Zobrazit plný text záznamu

Validation-Based Insertional Mutagenesis (VBIM), a powerful forward genetic screening strategy

Autor: Sarmishtha De, Ilaria Tamagno, George R. Stark, Mark W. Jackson

Publikováno v: Curr Protoc

Forward genetics begins with a biological phenotype and attempts to identify genetic changes that influence that phenotype. These changes can be induced in a selected group of genes, for instance, by using libraries of cDNAs, shRNAs, CRISPR guide RNA

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46a54e8ed22bf2c61fed147c0075beac
https://europepmc.org/articles/PMC8969887/

Zobrazit plný text záznamu

The ubiquitin E3 ligase FBXO22 degrades PD-L1 and sensitizes cancer cells to DNA damage

Autor: Sarmishtha De, Kala Mahen, George R. Stark, Belinda Willard, Elise G. Holvey-Bates

Publikováno v: Proc Natl Acad Sci U S A

High expression of programmed death-ligand 1 (PD-L1) in cancer cells drives immune-independent, cell-intrinsic functions, leading to resistance to DNA-damaging therapies. We find that high expression of the ubiquitin E3 ligase FBXO22 sensitizes nonsm

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2a11c4ddff180b99474c9cb3fb9e2b0
https://pubmed.ncbi.nlm.nih.gov/34795058

Zobrazit plný text záznamu

CBL0137 increases the targeting efficacy of Rovalpituzumab tesirine against tumour-initiating cells in small cell lung cancer

Autor: Yvonne Parker, Gary Wildey, George R. Stark, Daniel J. Lindner, Sarmishtha De, Afshin Dowlati

Publikováno v: British Journal of Cancer

Small cell lung cancer (SCLC) is characterised by high relapse rates. Tumour-initiating cells (TICs) are responsible for drug resistance and recurrence of cancer. Rovalpituzumab tesirine (Rova-T), a potent humanised antibody–drug conjugate, selecti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be934c05e00348fd3585204914f638e8
https://doi.org/10.1038/s41416-020-01192-x

Zobrazit plný text záznamu

The FACT inhibitor CBL0137 Synergizes with Cisplatin in Small-Cell Lung Cancer by Increasing NOTCH1 Expression and Targeting Tumor-Initiating Cells

Autor: Afshin Dowlati, Sarmishtha De, Daniel J. Lindner, Claire J. Coleman, Gary Wildey, George Stark Stark

Publikováno v: Cancer Research. 78:2396-2406

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1c2a87089f12faa79bb18b71dccc8e0d
https://doi.org/10.1158/0008-5472.can-17-1920

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání